Last reviewed · How we verify
NCT05245552
A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
Phase 3 trial testing Quadrivalent influenza vaccine(0.25ml) in Seasonal Influenza in 217 participants. Completed in 4 August 2023.
4 August 2023
Quick facts
| Lead sponsor | Sinovac Biotech Co., Ltd |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 217 |
| Start date | 8 August 2022 |
| Primary completion | 4 August 2023 |
| Estimated completion | 4 August 2023 |
| Sites | 4 locations across China |
Drugs / interventions tested
- Quadrivalent influenza vaccine(0.25ml) — full drug profile →
- Quadrivalent influenza vaccine(0.5ml) — full drug profile →
- Trivalent influenza vaccine(BV) — full drug profile →
- Trivalent influenza vaccine(BY) — full drug profile →
Conditions studied
- Seasonal Influenza — all drugs for Seasonal Influenza →
Sponsor
Sinovac Biotech Co., Ltd — full company profile →
Who can join
Adults 6 Months to 35 Months, any sex, with Seasonal Influenza. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study of quadrivalent influenza vaccine manufactured by Sinovac Biotech Co., Ltd will conduct in two phases,the phaseⅠclinical trial of the study will be open-label design,and the phase III clinical trial of the study will be randomized, double-blind, active controlled design.the purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy subjects aged 6 to 35 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05245552
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Quadrivalent influenza vaccine(0.25ml)
Trials testing the same drug.
- NCT06049927 — A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months · Phase 3 · completed
Other recruiting trials for Seasonal Influenza
Currently open trials in the same condition.
- NCT06863142 — Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP · Phase 1 · recruiting
Other Sinovac Biotech Co., Ltd trials
Trials by the same sponsor.
- NCT07418229 — Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine · Phase 1 · not yet recruiting
- NCT07416110 — Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine · Phase 3 · not yet recruiting
- NCT07055295 — Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen · Phase 3 · not yet recruiting
- NCT07055893 — Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen · Phase 3 · not yet recruiting
- NCT07400003 — Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05245552 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sinovac Biotech Co., Ltd
- Last refreshed: 28 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05245552.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing